- Mineralys Therapeutics' Phase 2 trial for lorundrostat shows significant blood pressure reduction in uncontrolled hypertension patients.
- The study's results are published in the prestigious New England Journal of Medicine.
- Lorundrostat demonstrates consistent efficacy across diverse patient groups with a favorable safety profile.
Mineralys Therapeutics, Inc. (MLYS, Financial) has announced the publication of its pivotal Phase 2 Advance-HTN trial results in the New England Journal of Medicine. The study assessed the efficacy of lorundrostat in patients with uncontrolled or resistant hypertension, achieving a 15.4 mmHg absolute reduction in 24-hour ambulatory blood pressure and a 7.9 mmHg placebo-adjusted reduction at week 12 (p=0.001).
The trial demonstrated lorundrostat's consistent efficacy across various patient demographics, including those on different baseline medications, genders, and among white and black patients. Importantly, the treatment showcased a favorable safety profile, with modest changes in key parameters like potassium, sodium, and estimated glomerular filtration rate (eGFR).
The publication underscores the potential of lorundrostat as a novel therapeutic addressing dysregulated aldosterone, an unaddressed driver of hypertension. The findings validate the clinical significance of lorundrostat, suggesting its potential role in significantly reducing cardiovascular events in this difficult-to-treat population.
"This publication marks a significant milestone, highlighting both the strength of our clinical data and the transformative potential of our treatments for hypertension," stated Jon Congleton, CEO of Mineralys Therapeutics. The company plans to release additional Phase 3 Launch-HTN trial data at an upcoming medical conference, further solidifying lorundrostat’s clinical promise.
